Skip to main content

$0.028 -0.001 (-3.45%)

High

$0.03

Low

$0.03

Trades

20

Turnover

$17,485

Volume

622,600
30 June 2023 at 4:10pm
Register to track NYR and receive email alerts.
Subject
NYR Ann: Brain Injury Program Update and Pathway to Phase I

NYR Ann: Cholesterol-Lowering Program Pathway to Phase I

NYR Ann: Release of Securities from Escrow

NYR Ann: Nyrada Annual General Meeting Results

NYR Ann: Annual General Meeting Presentation

NYR Ann: Nyrada AGM 2021 Chairman's Address

NYR Ann: Nyrada Quarterly Activities Report & Appendix 4C

NYR Ann: 2021 AGM Notice of Meeting and Proxy

NYR Ann: 2021 AGM Letter to Shareholders and Proxy

NYR Ann: Presentation to ASX Small and Mid-Cap Conference

NYR Ann: Updated Share Trading Policy

NYR Ann: Nyrada Reports Full Year FY2021 Results

NYR Ann: Annual Report to 30 June 2021

NYR Ann: Preliminary Final Report

NYR Ann: Appendix 4G and Corporate Governance Statement

NYR Ann: NYX-PCSK9i In Vivo Study Exploratory Analysis Results

NYR Ann: Nyrada Announces US Patent Grant for PCSK9 Inhibitor

NYR Ann: Nyrada Quarterly Activities Report & Appendix 4C

NYR Ann: Change of Director's Interest Notice - CC

NYR Ann: Change of Director's Interest Notice - ID

NYR Ann: Change of Director's Interest Notice - RW

NYR Ann: Change of Director's Interest Notice - MF

NYR Ann: Change of Director's Interest Notice - PM

NYR Ann: Change of Director's Interest Notice - JM

NYR Ann: Change in substantial holding

NYR Ann: Change in substantial holding

NYR Ann: Cleansing Statement

NYR Ann: Confirmation of Capital Structure, CDIs on Issue

NYR Ann: Notification regarding unquoted securities - NYR

NYR Ann: Application for quotation of securities - NYR

NYR Ann: Application for quotation of securities - NYR

NYR Ann: NYX-PCSK9i with Statin Achieves 65% Cholesterol Reduction

NYR Ann: Results of Meeting

NYR Ann: Improved Drug Candidate Selected for WRAIR Studies

NYR Ann: Notice of Extraordinary General Meeting/Proxy Form

NYR Ann: Nyrada Receives A$1.0M R&D Tax Incentive Rebate

NYR Ann: NYR Announces New Potent Cholesterol-Lowering Candidates

NYR Ann: Change of Registered Office and Principal Place of Business

NYR Ann: Nyrada Quarterly Activities Report & Appendix 4C

NYR Ann: Change in substantial holding

NYR Ann: Ceasing to be a substantial holder

NYR Ann: Change in substantial holding

NYR Ann: Cleansing Statement

NYR Ann: Appendix 2A

NYR Ann: Change in substantial holding

NYR Ann: Proposed issue of Securities - NYR

NYR Ann: Nyrada Receives Firm Commitments to Raise A$11 Million

NYR Ann: Nyrada Investor Presentation

NYR Ann: Trading Halt

NYR Ann: Change of Director's Interest Notice - JM

Register to track NYR and receive email alerts.

Similar Companies

CAN
CPH
EOF
IHL
MVP
MYX
NEU
PBP
RCE
SPL